How will you select patients with brain metastases for TTFields?

The METIS trial restricted eligibility only to patients with brain metastases from non-small cell lung cancer. Therefore, we would not be able to extrapolate these results and data to other tumor types and histologies. Indeed, a post hoc analysis of the data did demonstrate a greater impact in patie...

I congratulate the authors on a well-designed and conducted trial asking an important question. I currently offer TTF to my GBM patients, and some choose to use it.

I would like to see a cost-effectiveness analysis of TTF in this setting. Time to neurocognitive failure, OS, and radiological response...